Surgery Partners, Inc. (SGRY) Reaches $16.00 After 3.00% Down Move; 2 Analysts Are Bullish James Hardie Industries plc (JHX) Last Week

April 26, 2018 - By Vivian Currie

James Hardie Industries plc (NYSE:JHX) Logo

Among 2 analysts covering James Hardie Industries plc. (NYSE:JHX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. James Hardie Industries plc. had 3 analyst reports since August 15, 2016 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, August 15 by Citigroup. The stock of James Hardie Industries plc (NYSE:JHX) earned “Outperform” rating by CLSA on Friday, April 21. The firm earned “Buy” rating on Friday, November 10 by Citigroup. See James Hardie Industries plc (NYSE:JHX) latest ratings:

10/11/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade

The stock of Surgery Partners, Inc. (NASDAQ:SGRY) is a huge mover today! The stock decreased 2.74% or $0.45 during the last trading session, reaching $16. About 131,147 shares traded. Surgery Partners, Inc. (NASDAQ:SGRY) has declined 14.47% since April 26, 2017 and is downtrending. It has underperformed by 26.02% the S&P500.The move comes after 6 months negative chart setup for the $783.00 million company. It was reported on Apr, 26 by Barchart.com. We have $15.52 PT which if reached, will make NASDAQ:SGRY worth $23.49 million less.

Surgery Partners, Inc., through its subsidiaries, operates surgical facilities in the United States. The company has market cap of $783.00 million. The firm operates through three divisions: Surgical Facility Services, Ancillary Services, and Optical Services. It currently has negative earnings. The Company’s surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastrointestinal, general surgery, ophthalmology, orthopedics, and pain management.

Among 10 analysts covering Surgery Partners (NASDAQ:SGRY), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. Surgery Partners had 29 analyst reports since October 26, 2015 according to SRatingsIntel. Goldman Sachs initiated the shares of SGRY in report on Monday, October 26 with “Neutral” rating. The stock of Surgery Partners, Inc. (NASDAQ:SGRY) earned “Buy” rating by Stifel Nicolaus on Tuesday, October 27. The company was maintained on Friday, August 11 by Citigroup. The firm has “Buy” rating by Citigroup given on Monday, March 14. The stock has “Buy” rating by RBC Capital Markets on Monday, July 17. As per Wednesday, June 21, the company rating was maintained by Stifel Nicolaus. The firm has “Strong Buy” rating given on Monday, October 26 by Raymond James. KeyBanc Capital Markets maintained the shares of SGRY in report on Wednesday, September 20 with “Hold” rating. On Monday, October 26 the stock rating was initiated by RBC Capital Markets with “Outperform”. The firm has “Buy” rating by Benchmark given on Tuesday, January 31.

Analysts await Surgery Partners, Inc. (NASDAQ:SGRY) to report earnings on May, 8. They expect $-0.21 earnings per share, down 625.00% or $0.25 from last year’s $0.04 per share. After $-0.03 actual earnings per share reported by Surgery Partners, Inc. for the previous quarter, Wall Street now forecasts 600.00% negative EPS growth.

James Hardie Industries plc, together with its subsidiaries, makes and sells fiber cement products. The company has market cap of $7.88 billion. It operates through four divisions: North America Fiber Cement, International Fiber Cement, Other Business, and Research and Development. It has a 31.93 P/E ratio. The firm offers fiber cement interior linings, fiberglass windows, exterior siding products, and related accessories products.

Surgery Partners, Inc. (NASDAQ:SGRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Currie

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts